Indicative text IMI 2 Call 1 published

IMI (Innovative Medicines Initiative) has published an indicative topic text for IMI 2-Call 1. The call comprises 2 topics, namely Translational approaches to disease modifying therapy of Type 1 Diabetes Mellitus (T1DM) and Discovery and validation of novel endpoints in retinal diseases. More information about the new call will become available once the topics have been finalised. Read the indicative topic text here.

The goal of the IMI 2 is to develop next generation vaccines, medicines and treatments, such as new antibiotics. It will build on the successes and lessons learnt under IMI. Like IMI, it will bring together companies, universities, public laboratories, innovative small and medium-sized enterprises (SMEs), patient groups and regulators in collaborative projects that will pave the way for breakthrough vaccines, medicines and treatments to tackle Europe’s growing health challenges, and secure the future international competitiveness of Europe’s pharmaceutical industry.

The Innovative Medicines Initiative (IMI) is Europe's largest public-private partnership aiming to improve the drug development process by supporting a more efficient discovery and development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in Europe that will boost innovation in healthcare. Acting as a neutral third party in creating innovative partnerships, IMI aims to build a more collaborative ecosystem for pharmaceutical research and development (R&D). IMI will provide socio-economic benefits to European citizens, increase Europe's competitiveness globally and establish Europe as the most attractive place for pharmaceutical R&D.